10 Cancer Treatment Approvals From September 2026 and What They Mean for You

September 2026 was a busy month for the Food and Drug Administration (FDA), with new options for several cancers that have had few choices. Here's a plain-language guide to each decision, who it's for and what it could mean for your care. (For last month's list, see 6 Cancer Drugs FDA Approved in August 2026 and What They Mean for You.)

1. Etcamah for ESR1-Mutated Breast Cancer

Approved: Sept. 4 (accelerated approval) | Read more

Etcamah (camizestrant), taken with a CDK4/6 inhibitor, is for HR-positive, HER2-negative advanced breast cancer when a blood test finds an ESR1 mutation during first-line treatment, before scans show growth. In the SERENA-6 trial, people who switched went a median of 16 months before their cancer progressed, vs 9.2 months for those who didn't. CURE first covered the trial when results showed the switch delayed progression.

What it means for you: It is the first approval built around regular blood testing (liquid biopsy) during treatment. Doctors are still debating how widely to use this approach, so ask whether repeat blood tests make sense for you. Side effects to know: brief flashes of light in vision and a slower heart rate.

2. Hyrnuo as a First Treatment for HER2-Mutant Lung Cancer

Approved: Sept. 9 (accelerated approval) | Read more

Hyrnuo (sevabertinib), a pill, can now be used as the first treatment for advanced nonsquamous non-small cell lung cancer with certain HER2 mutations. In 69 previously untreated patients, tumors shrank in 75%. A larger trial is underway to confirm the benefit.

What it means for you: HER2 mutations are found only with biomarker testing of the tumor or blood. If you have advanced lung cancer, make sure that testing was done before starting treatment.

3. A Shorter Hospital Stay for Imdelltra

Label update: Sept. 14

People starting Imdelltra (tarlatamab) for extensive-stage small cell lung cancer now need 6 to 8 hours of monitoring after each of their first two doses, down from 22 to 24 hours. Patients must still stay within an hour of a medical facility, with a caregiver, for 48 hours after each of those doses.

What it means for you: Less time in the hospital could make Imdelltra easier to start, especially for people who live far from a cancer center. When the drug was first approved in 2024, Dr. Roy Herbst of Yale Cancer Center told CURE, "This accelerated approval of Imdelltra really is something that is great for patients," noting how few options people with small cell lung cancer had. Read more in Imdelltra for Small Cell Lung Cancer Addresses Key Unmet Needs.

4. Ameluz Light Therapy for a Common Skin Cancer

Approved: Sept. 14

Ameluz gel with red-light photodynamic therapy is now approved for superficial basal cell carcinoma, the first light-based treatment the FDA has approved for a skin cancer. In its phase 3 trial, lesions fully cleared in about 66% of patients vs about 5% with placebo.

What it means for you: For a thin, surface-level basal cell carcinoma, this offers a nonsurgical option done in a dermatologist's office. Ask whether your lesion is the superficial type and how it would be checked afterward.

5. Pixclara Brain Tumor Scan

Approved: Sept. 14

Pixclara is the first FDA-approved FET-PET imaging agent for glioma. It helps doctors tell whether a change on MRI after treatment is the tumor coming back or a side effect of treatment.

What it means for you: Waiting to learn what a new spot on a scan means is one of the hardest parts of living with a brain tumor. A clearer answer can help avoid unnecessary surgery or a delay in treatment. Ask whether this scan is available at your center.

6. Bexlutry for Neuroendocrine Tumors

Approved: Sept. 14

Bexlutry is a new version of lutetium Lu 177 dotatate, a radiation-delivering treatment for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It was approved based on its similarity to Lutathera.

What it means for you: A second source of this treatment could help with supply and access. The treatment itself is the same type of radioligand therapy many people with GEP-NETs already receive.

7. Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer

Approved: Sept. 18 (full approval) | Read more

This all-oral combination is for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer that has grown after at least one hormone therapy. In EMBER-3, people with ESR1 mutations went a median of 11.1 months before progression on the combination, vs 5.5 months on Inluriyo (imlunestrant) alone.

What it means for you: It's the second ESR1-focused breast cancer approval this month, and both are pills, which can mean fewer infusion visits. CURE's 5 Years of Breast Cancer Advances explains how these options fit together.

8. Bravnetsa for Neuroendocrine Tumors

Approved: Sept. 22 | Read more

Bravnetsa is the first radioligand therapy approved through the FDA's generic pathway, judged equivalent to Lutathera for SSTR-positive GEP-NETs.

What it means for you: With two new versions of this treatment approved in September, people with GEP-NETs may find it easier to get radioligand therapy. Ask your care team which version your center uses and whether it affects your insurance coverage.

9. Lyrfigtu for FGFR2-Positive Bile Duct Cancer

Approved: Sept. 23 | Read more

Lyrfigtu (lirafugratinib), a once-daily pill, is for previously treated cholangiocarcinoma with an FGFR2 fusion or rearrangement. Tumors shrank in 46% of patients, and responses lasted a median of 11.8 months.

What it means for you: Only tumor testing can find an FGFR2 change, so ask whether your bile duct cancer has been tested. Side effects to know: nail changes, hand-foot skin reactions and mouth sores were very common, so tell your team early if they start.

10. Welireg Plus Lenvima for Advanced Kidney Cancer

Approved: Sept. 24 | Read more

For clear cell kidney cancer that has grown after immunotherapy, Welireg (belzutifan) plus Lenvima (lenvatinib) delayed progression longer than Cabometyx (cabozantinib): a median of 14.6 vs 10.6 months. The difference in overall survival was not statistically significant.

What it means for you: Welireg is already familiar to many people with kidney cancer. Mark Hilz, a patient who has taken it, told CURE, "All I have to do to treat myself is go to bed and take three pills," in Welireg Helps a Patient With RCC Live a 'Very Normal Lifestyle'. The combination does add Lenvima's side effects. CURE's guide to what patients with kidney cancer need to know about Welireg covers what to watch for. Side effects to know: anemia, high blood pressure, diarrhea and fatigue.

One Approval That Was Taken Away

On Sept. 1, the FDA withdrew the accelerated approval of Krazati (adagrasib) plus Erbitux (cetuximab) for KRAS G12C-mutated colorectal cancer after a confirmatory trial did not show that it helped people live longer than chemotherapy. Read CURE's coverage. Krazati is still approved for lung cancer. If you are taking this combination for colorectal cancer, don't stop on your own; talk with your oncologist about next steps.

The Bigger Picture

Taken together, September's decisions show where cancer care is heading. Many of these approvals depend on knowing the specific makeup of a tumor, whether that's an ESR1 mutation found in a blood test, a HER2 mutation in lung cancer or an FGFR2 change in bile duct cancer. Others, like the shorter monitoring time for Imdelltra and the new versions of radioligand therapy, are about making existing treatments easier to get.

The Krazati withdrawal is a reminder that early approvals still have to prove themselves in larger trials. That process can be frustrating, but it is designed to make sure the treatments patients rely on truly help them live longer or better.

No single approval is right for everyone. The most useful step you can take is to make sure your cancer has had the testing it needs and to ask your care team whether anything new this month could fit your situation, now or down the road.

References:

1. U.S. Food and Drug Administration. "FDA Grants Accelerated Approval to a New Breast Cancer Treatment." Sept. 4, 2026.
2. Healio. "FDA OKs Accelerated Approval to Frontline Hyrnuo for Non-Small Cell Lung Cancer." Sept. 9, 2026.
3. Biofrontera. "Biofrontera Announces FDA Approval of Ameluz Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma." GlobeNewswire, Sept. 14, 2026.
4. Curium. "Curium Announces FDA Approval of Bexlutry Lutetium Lu 177 Dotatate Injection for Adults With SSTR-Positive GEP-NETs." Sept. 14, 2026.
5. The ASCO Post. "FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer." Sept. 18, 2026.
6. Cancer Therapy Advisor. "FDA Approves Bravnetsa as Equivalent to Lutathera for GEP-NETs." Sept. 25, 2026.